Savient's Krystexxa Wins Advisory Cmte. Endorsement
This article was originally published in The Pink Sheet Daily
Executive Summary
In light of a cardiovascular signal but insufficient data, panel recommends a REMS with provider registration for the orphan biologic.
You may also be interested in...
Miles To Go Before Savient Krystexxa Approval; REMS Talks Are Next Step
Now that gout drug candidate Krystexxa has passed muster with FDA's Arthritis Drugs Advisory Committee, its next major hurdle is agency approval. But with only six weeks to go until its Aug. 1 user fee date and what's expected to be a fairly complex Risk Evaluation and Mitigation Strategy, odds are FDA will be unable to meet that timeline
Miles To Go Before Savient Krystexxa Approval; REMS Talks Are Next Step
Now that gout drug candidate Krystexxa has passed muster with FDA's Arthritis Drugs Advisory Committee, its next major hurdle is agency approval. But with only six weeks to go until its Aug. 1 user fee date and what's expected to be a fairly complex Risk Evaluation and Mitigation Strategy, odds are FDA will be unable to meet that timeline
Febuxostat Approval Still Leaves Many Questions For Lively Gout Market
FDA's mid-February approval of Takeda's oral gout drug Uloric (febuxostat) may have come as no surprise, given an advisory panel's positive recommendation in November, but the gout market itself could take some curious turns as therapy models shake out and other candidates line up for approvals